1066 related articles for article (PubMed ID: 26752337)
21. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
23. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
24. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
[TBL] [Abstract][Full Text] [Related]
25. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
26. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study.
Chen CB; Lin M; Eurich DT; Johnson JA
Clin Ther; 2016 Jun; 38(6):1392-1400. PubMed ID: 27061884
[TBL] [Abstract][Full Text] [Related]
27. Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.
Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
JAMA Pediatr; 2020 Jun; 174(6):543-551. PubMed ID: 32176276
[TBL] [Abstract][Full Text] [Related]
28. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study.
Chen LY; Lin HJ; Wu WT; Chen YC; Chen CL; Kao J; You SL; Chou YC; Sun CA
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33182362
[TBL] [Abstract][Full Text] [Related]
29. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study.
Hung SC; Liao KF; Hung HC; Lin CL; Lai SW; Lee PC; Hung SR
Fam Pract; 2018 Mar; 35(2):166-171. PubMed ID: 29045621
[TBL] [Abstract][Full Text] [Related]
30. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Liew JW; Peloquin C; Tedeschi SK; Felson DT; Zhang Y; Choi HK; Terkeltaub R; Neogi T
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2059-2065. PubMed ID: 35245410
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
Aliment Pharmacol Ther; 2012 Nov; 36(9):866-74. PubMed ID: 22966967
[TBL] [Abstract][Full Text] [Related]
32. Coffee Consumption and Incident Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study.
Hu EA; Selvin E; Grams ME; Steffen LM; Coresh J; Rebholz CM
Am J Kidney Dis; 2018 Aug; 72(2):214-222. PubMed ID: 29571833
[TBL] [Abstract][Full Text] [Related]
33. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
35. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
36. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children.
Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
JAMA Pediatr; 2021 Apr; 175(4):394-403. PubMed ID: 33555324
[TBL] [Abstract][Full Text] [Related]
37. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
38. Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study.
Min YW; Kang D; Shin JY; Kang M; Park JK; Lee KH; Lee JK; Lee KT; Rhee PL; Kim JJ; Guallar E; Cho J; Lee H
Aliment Pharmacol Ther; 2019 Oct; 50(7):760-768. PubMed ID: 31448440
[TBL] [Abstract][Full Text] [Related]
39. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population.
Devraj R; Deshpande M
Res Social Adm Pharm; 2020 Jun; 16(6):776-782. PubMed ID: 31445985
[TBL] [Abstract][Full Text] [Related]
40. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
